Union Jobs Report
PILMA news
President McManus Letter on PBMs to Congress
November 21, 2024 Dear Speaker Johnson, Leader Jeffries, Leader Schumer, and Leader McConnell, As Congress returns to Washington for the remaining weeks of the legislative session, lawmakers have a critical opportunity to deliver meaningful reforms that will provide relief to millions of hardworking families struggling with high prescription drug costs.
United Association President McManus Letter to HELP Committee
September 25, 2024 To:The Office of Senator Bernie Sanders, ChairU.S. Senate Committee on Health, Education, Labor, and Pensions332 Dirksen Senate Office Bldg. Washington, D.C., 20510 The Office of Senator Bill Cassidy, Ranking MemberU.S. Senate Committee on Health, Education, Labor, and Pensions455 Dirksen Senate Office Bldg.Washington, D.C., 20510 cc: Members of
STATEMENT CONCERNING CMS’ Announcement of 10 Drugs Selected for 2026 Government Price Controls
August 13, 2024Today, the Centers for Medicare and Medicaid Services (CMS) released the Maximum Fair Prices (MFPs) for 10 selected medicines to go into effect in 2026. PILMA reiterates our opposition to MFPs, which are simply government price controls on medicines in Medicare under the guise of negotiation. PILMA has
STATEMENT Supporting the House Oversight Committee Hearings on PBM Transparency and Accountability
July 23, 2024 The labor and industry partners of the Pharmaceutical Industry Labor- Management Association (PILMA) applaud the House Oversight Committee’s investigation into the role of PBMs in prescription drug markets. PILMA has a long history of supporting increased transparency and accountability in the prescription drug supply chain and has
